Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CC said it himself - he can’t believe how far such small company has got to and think about this:
With Lonza, Intel and rumours on Gilead and Viiv - its not small businesses we “ENZC” are dealing with - combined over $400 billion market cap between them - remember Viiv is 76.5% owned by GlaxoSmithKline.
Uplist to NYSE - anyone know or had experience with other partnerships where a similar sized company like Lonza would require a partner to be uplisted to NYSE in order to do serious business? Just wondering if next weeks PR could have some extra goodies in their sleeves :)
Lonza - Worlds 344th largest company based on market cap!!
Lonza growth 100% last 18 months during Covid - wauw.
What a great choice #ENZC team
A few numbers about Lonza:
LONZA GROUP
Market Value (Jan-01-2021)
47.276 Billion USD
Market Value (Jan 1st 2020)
27.306 Billion USD
Milestones - would like an updated PR in near future with status on all the Milestones from a few month back and which will give a good indication on how we are moving along - on time, time line going forward etc. #ENZC
Hold or Accumulate and be patient! No company sends out PR every week - last one was 6/14. Too many PR’s will also look out of the norm. #ENZC
Agreement w Rosetta Lifecare….
I send a message to Rosetta Lifecare asking them about further countries for distribution - they replied:
“Hi, we will announce the next list of countries as it becomes apparent.”
I am sure more countries will soon be added to the list:
Rosetta Lifecare signed with Enzolytics Inc. agreement on exclusive distribution rights for the distribution of their ITV1 product for the treatment of HIV / AIDS and Hepatitis C for the following countries: Pakistan, United Arab Emirates, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda Northern Sudan, Egypt, Morocco and Tunisia. The drug is in an inspection form based on the IPF platform and has shown very good results in clinical trials.
#ENZC
Interesting article from today!
https://www.streetinsider.com/dr/news.php?id=18634612&gfv=1
#2 Enzolytics (Medical Advisory Board includes Ronald Moss from Adamis).
#3 Adamis (Chief Medical Officer, Ronald Moss).
My guess: 3rd webcast w Intel
Havent heard much about Dr Moss’ presence on their advisory board and how he’ll be involved?
If you have sold your shares this week - you are truly not an Investor and have not done your DD - suggest its time to leave Investorshub.
#ENZC still listed as partner on front page @ Denver Scientific, lets see whats to come :)
Came across the chart for NVAX - also related to Texas A&M….
Jan 2020: $4.00
Mar 2020: $16.00
May 2020: $18.00
June 2020: $53.00
Aug 2020: $156.00
Oct 2020: $105.00
Dec 2020: $140.00
Apr 2021: $184.00
Today: $196.40
From $4 bucks to $196.40 in 17 months.
It can surely go fast and furious once companies gets FDA approval!!!!!
Pugsieboy….you are wasting your time….
When biking today I was thinking how huge this Intel connection actually is - INTEL contacted ENZC - remember that. Intel want to be a part of something huge and will help ENZC succeed.
Imagine - we went to $0.96 with hardly anything in the goodie bag - now look at the MANY “playing cards” we have - I would say that the future of #ENZC looks pretty good.
#UpwardsOnwards
Same here......but you know what.....I don’t regret it.
We are not even at the launch pad yet.....onwards and upwards!
Hopefully Fauci will not stand in the way....
Not much from Dr Moss yet but I’m sure he will make a statement in near future.
Exactly Brez - much more to come very very soon
Highlights I gathered:
1) Intel / ENZC are more than excited to work together and Intel is totally onboard!!
2) Animal trials set for June - was 6 month down the road in their April PR!
3) They’ve already spoken to FDA about expediting various!
4) Together Intel and ENZC have been in touch with Governments overseas about their work (Estonia was mentioned)
5) The host mentioned that Dr Chandra was halfway around the World?? Could he be visiting the Serum Institute of India?
You must listen to this interview - forget what happened early February and until now - onwards and upwards!
We “ENZC” have so many balls in the air that even the best circus juggling artist would never be able to catch them all - can’t wait to see our next plays.
Onwards and Upwards
In PR from last week they said they would announce another deal in Europe this week...
Deal must be done already IMO - very excited about whats to come.
Onwards and Upwards
PR coming very soon about another deal in Europe.....
One wheel left + spare tire.....who’ll be the last two companies to join our wagon?
More than one PR in the coming week - can’t wait!!
Which Pharma company will join the ENZC/ Intel wagon as the 3rd wheel?
UPLIST coming soon.....I’ve seen one OTC update on a Saturday evening a few months back.
And to add from their PR 5/12:
“As a result of his efforts, we have another European transaction which we expect to consummate and report in the coming week.”
No official PR from us yet? Must be coming....
Told friends I would run around the big Intel plant which is nearly in my backyard here in southeast Phoenix if a partnership w Intel came along - holding a huge ENZC sign - guess its time to get the running shoes on!!!!
Let’s see if CNBC will mention this collaboration in the next days
wauw - good Friday morning start - and coming week(s) will be interesting to watch
I bet that next weeks news is about this PR from 3/22:
Additionally, the Company has entered negotiations with Pro Wave Ad Product ("PWA"), a Bulgarian Company, to supply the raw material for PWA's Contract in India for the production of a spray modulating the immune system under U.S. Patent No. 8,309,072 owned by Zhabilov Trust. This contract is valued at more than $50 million to PWA. This is the only approved use of this technology as a nutraceutical. The FDA issued a nutraceutical number to Harry Zhabilov on October 12, 2018. The first delivery under this agreement with PWA is expected to be in late spring 2021. The value to the Company is yet to be determined.
The spray product is a nutraceutical application, separate from the ITV-1 treatment that successfully completed Phase 3 clinical trials on August 7, 2014, with the Final Report being issued in November of 2016 by Assoc. Prof. Ivaylo Elenkov, MD, Chief researcher at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases. This report and the associated clinical trials were conducted under Bulgarian Drug Administration (BDA) guidelines. With Bulgaria joining the EMA in April of 2019, the BDA can no longer issue permits for mass use for the HIV/AIDS virus. Under the Company's new business arrangement with International Medical Partners, Ltd. (IMBL), new clinical trials are being planned and scheduled with Clinical Design, a Clinical Research Organization (CRO) in Bulgaria. The Company is finalizing negotiations with a Contract Manufacturer, also located in Bulgaria, for the production of the ITV-1 Immunotherapy treatment. The new clinical trials for the Patented and licensed ITV-1 treatment under the EMA guidelines will be submitted upon completion. When the EMA permit for mass use is issued, the Company plans to pursue Federal Drug Administration (FDA) approval under the Mutual Recognition Agreement between the FDA and EMA.
As a result of the necessity to perform Clinical trials under the EMA guidelines, the agreements with IMMB BG, which were in default, have been cancelled and superseded by the new agreements with IMBL and PAW.
Harry Zhabilov, CSO, stated, "With our new partners at IMBL, the CRO and the CMO, all located in Bulgaria, and all experienced in the EMA Permitting process, the next steps in bringing our Immunotherapy Treatment for HIV/AIDS and hepatitis C viruses to a point of approval by the EMA is on the right path. The contract being negotiated with PAW is expected to produce meaningful revenue generated from our technology."
Nope BUD - they just send out their Financials today - also you missed the COO’s update about the same - You are late LOL
Quaterly Report - Financials is out this morning!
https://backend.otcmarkets.com/otcapi/company/financial-report/282626/content